Increased expression of G9a and/or DNMT1 is associated with disease progression and poor outcome in patients with MM. (A) Protein-protein interaction network of G9a (EHMT2). (B-E) Selection of normalized (MAS5) expression of DNMT1 and G9a genes from CD138+ normal BMPCs, MGUS, patients with smMM, MM and PCL (U133 Plus 2.0; Affymetrix GSE5900 and GSE2113). Statistical analysis was performed with multiple Kruskal-Wallis test. Values presented with standard error of the mean (SEM). (F) Normalized (MAS5) G9a expression-based survival data of patients with MM not responding to bortezomib monotherapy (U133 Plus 2.0; Affymetrix, GSE9782). The analysis was performed on GenomicScape using log-rank test. (G) G9a expression-based survival data of patients with MM from MMRF-CoMMpass. (H) Normalized (MAS5) DNMT1 expression-based survival data of patients with MM not responding to bortezomib monotherapy (U133 Plus 2.0; Affymetrix, GSE9782). The analysis was performed on GenomicScape using log-rank test. (I) DNMT1 expression-based survival data of patients with MM from MMRF-CoMMpass. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. MMRF, Multiple Myeloma Research Foundation; PCL, PC leukemia; smMM, smoldering MM.
Figure 1.

Increased expression of G9a and/or DNMT1 is associated with disease progression and poor outcome in patients with MM. (A) Protein-protein interaction network of G9a (EHMT2). (B-E) Selection of normalized (MAS5) expression of DNMT1 and G9a genes from CD138+ normal BMPCs, MGUS, patients with smMM, MM and PCL (U133 Plus 2.0; Affymetrix GSE5900 and GSE2113). Statistical analysis was performed with multiple Kruskal-Wallis test. Values presented with standard error of the mean (SEM). (F) Normalized (MAS5) G9a expression-based survival data of patients with MM not responding to bortezomib monotherapy (U133 Plus 2.0; Affymetrix, GSE9782). The analysis was performed on GenomicScape using log-rank test. (G) G9a expression-based survival data of patients with MM from MMRF-CoMMpass. (H) Normalized (MAS5) DNMT1 expression-based survival data of patients with MM not responding to bortezomib monotherapy (U133 Plus 2.0; Affymetrix, GSE9782). The analysis was performed on GenomicScape using log-rank test. (I) DNMT1 expression-based survival data of patients with MM from MMRF-CoMMpass. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. MMRF, Multiple Myeloma Research Foundation; PCL, PC leukemia; smMM, smoldering MM.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal